Enabling Synthesis of Triple Reuptake Inhibitor (+)-BMS-820836, a Potential Therapeutic Agent for the Treatment of Depression-Reference-Cited by-同舟云学术

Enabling Synthesis of Triple Reuptake Inhibitor (+)-BMS-820836, a Potential Therapeutic Agent for the Treatment of Depression

Published:2016-01-04 Issue:1 Volume:20 Page:44-50
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Lobben Paul C.¹,Amin Rasidul²,Chen Bang-Chi³,Cui Wenge⁴,Hu Min⁴,Isherwood Matthew⁴,Liu Shuang⁴,Nacro Kassoum⁴,Miles Brandon²,Mobele Bingidimi²,Olson Richard E.⁵,Wang Bei³,Yang Yuh-Lin⁴,Zhao Rulin³

Affiliation:

1. Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New Jersey 08903, United States

2. Chemical Development Department, Albany Molecular Research, Inc., 21 Corporate Circle, Albany, New York 12203, United States

3. Discovery Chemistry, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States

4. Medicinal Chemistry Department, Albany Molecular Research, Inc., 26 Corporate Circle, Albany, New York 12203, United States

5. Neuroscience Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.5b00261

Reference33 articles.

1. Global burden of depressive disorders in the year 2000

2. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States

3. Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication

4. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

5. Partial Response and Nonresponse to Antidepressant Therapy